{"entity":{"id":"nct07033026","kind":"trial","name":"An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.","aka":[],"tldr":"A phase 2 trial of NGM120 Q4W in colorectal cancer, run by NGM Biopharmaceuticals, Inc, now recruiting.","summary":"An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia. is a phase 2 interventional study registered as NCT07033026 by NGM Biopharmaceuticals, Inc, with 136 participants planned, started 2025-06-25 and due to reach its primary completion in 2027-04. Interventions recorded: NGM120 Q4W, NGM120 Q8W and Placebo given.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07033026","url":"https://clinicaltrials.gov/study/NCT07033026"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07033026","phase":"2","setting":"A Phase 2, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of NGM120 in Participants With Colorectal Cancer Who Have Cancer Cachexia","sponsor":"NGM Biopharmaceuticals, Inc","enrolled":136,"outcomes":[]},"route":"/trials/nct07033026/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}]}}